Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program

被引:511
作者
Shah, RB
Mehra, R
Chinnaiyan, AM
Shen, RL
Ghosh, D
Zhou, M
MacVicar, GR
Varambally, S
Harwood, J
Bismar, TA
Kim, R
Rubin, MA
Pienta, KJ
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Med Oncol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[6] Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
关键词
D O I
10.1158/0008-5472.CAN-04-2442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Understanding the biology of prostate cancer metastasis has been limited by the lack of tissue for study. We studied the clinical data, distribution of prostate cancer involvement, morphology, immunophenotypes, and gene expression from 30 rapid autopsies of men who died of hormone-refractory prostate cancer. A tissue microarray was constructed and quantitatively evaluated for expression of prostate-specific antigen, androgen receptor, chromogranin, synaptophysin, MIB-1, and alpha-methyl-acylCoA-racemase markers. Hierarchical clustering of 16 rapid autopsy tumor samples was performed to evaluate the cDNA expression pattern associated with the morphology. Comparisons were made between patients as well as within the same patient. Metastatic hormone-refractory prostate cancer has a heterogeneous morphology, immunophenotype, and genotype, demonstrating that "metastatic disease" is a group of diseases even within the same patient. An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease.
引用
收藏
页码:9209 / 9216
页数:8
相关论文
共 45 条
[1]   Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors [J].
Agoff, SN ;
Lamps, LW ;
Philip, AT ;
Amin, MB ;
Schmidt, RA ;
True, LD ;
Folpe, AL .
MODERN PATHOLOGY, 2000, 13 (03) :238-242
[2]  
AMIN MB, 2003, GLEASON GRADING PROS, P116
[3]   NEUROENDOCRINE DIFFERENTIATION IN METASTATIC PROSTATIC ADENOCARCINOMA [J].
APRIKIAN, AG ;
CORDONCARDO, C ;
FAIR, WR ;
ZHANG, ZF ;
BAZINET, M ;
HAMDY, SM ;
REUTER, VE .
JOURNAL OF UROLOGY, 1994, 151 (04) :914-919
[4]  
Bauer KD, 2000, CLIN CANCER RES, V6, P3552
[5]  
Berges RR, 1995, CLIN CANCER RES, V1, P473
[6]   LATENT CARCINOMA AND ATYPICAL LESIONS OF PROSTATE - AN AUTOPSY STUDY [J].
BILLIS, A .
UROLOGY, 1986, 28 (04) :324-329
[7]   Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival [J].
Bostwick, DG ;
Qian, JQ ;
Pacelli, A ;
Zincke, H ;
Blute, M ;
Bergstralh, EJ ;
Slezak, JM ;
Cheng, L .
JOURNAL OF UROLOGY, 2002, 168 (03) :1204-1211
[8]   Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[9]   Molecular determinants of resistance to antiandrogen therapy [J].
Chen, CD ;
Welsbie, DS ;
Tran, C ;
Baek, SH ;
Chen, R ;
Vessella, R ;
Rosenfeld, MG ;
Sawyers, CL .
NATURE MEDICINE, 2004, 10 (01) :33-39
[10]   Androgen receptors in prostate cancer [J].
Culig, Z ;
Klocker, H ;
Bartsch, G ;
Hobisch, A .
ENDOCRINE-RELATED CANCER, 2002, 9 (03) :155-170